See every side of every news story
Published loading...Updated

Cantor Fitzgerald Downgrades Supernus Pharmaceuticals (NASDAQ:SUPN) to Neutral

Summary by americanbankingnews.com
Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) was downgraded by research analysts at Cantor Fitzgerald from an “overweight” rating to a “neutral” rating in a report issued on Wednesday, Marketbeat reports. They currently have a $36.00 target price on the specialty pharmaceutical company’s stock, down from their previous target price of $57.00. Cantor Fitzgerald’s price […]
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

americanbankingnews.com broke the news in on Friday, February 21, 2025.
Sources are mostly out of (0)